Hepatitis C

Researchers suggest a need exists for integration of hepatitis C treatment into all facets of addiction care for individuals who inject drugs.

New research suggests cirrhosis, not HCV status, is the reason diabetes rates are higher among HCV-infected patients.

A new analysis shows a combination of ombitasvir/paritaprevir, ribavirin, and dasabuvir is safe and effective among older patients with HCV and cirrhosis.

A new analysis shows fully one-third of patients prescribed direct-acting antivirals are denied coverage by their insurers. Denial rates are even higher for patients with private insurance.

ContraVir plans to begin a streamlined early clinical program to test the clinical safety and efficacy profile in healthy volunteers and HBV-infected patients.

A University of Surrey research professor has developed a mathematical model based on earlier models, for monitoring HCV progression and treatment response.

New research appears to show a causal link between HCV infection and dysbiosis of the gut microbiota.

A recent CDC report shows an association between the increase in HCV infections and the opioid crisis. Because HCV symptoms may not appear for decades, people often go undiagnosed, which delays treatment.

By the time of diagnosis, patients often have costly complications involving the liver.

The addition of ribavirin to direct-acting antiviral treatment of HCV with cryoglobulinemia aided to achieving immunological response.

HCV heightens the risk for kidney disease but, the disease's treatment improves rates of survival in patients on hemodialysis.

A higher prevalence of HCV in adults who received surgery for congenital heart disease as children is a "double whammy" when procedures leaves systemic venous congestion affecting hepatic veins, researchers said.

Eight weeks of ledipasvir and sofosbuvir for HCV genotype 1 was found as effective as 12 weeks in patients of different race and ethnicity despite guidelines recommending the shorter treatment for non-black patients.

A new assessment of the association between alcoholism and brain structure is emphasized by current data indicating a major increase of 106.7% in alcohol use disorder in the US population aged 65 years or older.

Results contradicted previous studies that did not account for baseline differences between DAA- and interferon-treated patients.

The approved use of a direct-acting antiviral combination for 8 weeks to treat HCV genotypes 1 and 3 was supported by data from over 1200 patients.

This research contradicts previous TDF studies that were not placebo-controlled.

The odds of reaching undetectable HCV RNA by 12 weeks were 57% less for African-Americans in the retrospective study.

A newly discovered hepatitis C virus (HCV) subtype harbors resistance-associated mutations to direct acting antivirals.

Elevated thyroid stimulating hormone was linked to female sex, higher BMI, liver fibrosis, AST, and low albumin.

To date, there has been no assessment of CMV reactivation and CV risk in liver transplant patients.

Treatment of HCV was associated with lower risk for other maladies in the largest western study of the relationship between antiviral treatment and extrahepatic conditions.

Researchers isolated the neurotoxic complex crotoxin from the venom of Crotalus durissus terrificus, commonly known as the South American rattlesnake.

Those in deprived populations—the homeless, those with substance abuse disorder, sex workers, and prisoners—have a significantly higher rate of all-cause mortality than their counterparts.

The CDC's committee voted unanimously to support the vaccine, widening its availability to patients through health care coverage and plans.

There has been only 1 study into the effect of viral eradication using interferon-based HCV therapy on the development of hepatic steatosis in patients with genotype 3 infection.

Former flaws in medical care may have driven the generation's rate of infection, but modern testing will improve it.

Spontaneous clearance peaks at 12 months, with 36.1% of patients achieving spontaneous clearance of HCV by that point in time.

DAAs have made the risk of HCV infection both manageable and ethically acceptable.